Skip to main content
. Author manuscript; available in PMC: 2021 Nov 17.
Published in final edited form as: Vaccine. 2020 Aug 30;38(49):7716–7727. doi: 10.1016/j.vaccine.2020.08.031

Figure 3.

Figure 3.

Percentages of adolescents (A) and young adults (B) with hSBA titres ≥LLOQ against the 4 primary and 10 additional MenB test strains following vaccination with MenB-FHbp, adapted with permission from Ostergaard et al. N Engl J Med. 2017;377:2349–2362 [76]. Strains are indicated by their corresponding FHbp sequence variants using Pfizer nomenclature (http://pubmlst.org/neisseria/fHbp). The LLOQ was 1:8 or 1:16 depending on test strain. FHbp=factor H binding protein; hSBA=serum bactericidal antibody assay using human complement; LLOQ=lower limit of quantitation; MenB=meningococcal serogroup B; MenB-FHbp= Trumenba®, bivalent rLP2086.